MarketPeel
Insider Trading Intelligence
KA

Kamran Alam

TSHA
CHIEF FINANCIAL OFFICER · TAYSHA GENE THERAPIES, INC. · CIK 0001793412
FILING MIX · LIFETIME53%/47%
BUYS
18
SELLS
16
TOTAL VALUE
$1.45M
COMPANIES
2
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
1,445,131
AVG SELL PX
$5.04
TRADE KIND
SHOWING 34 / 34
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
14 backtested trades · 8 horizons · 11 pending
Forward-return performance of every backtestable P/S trade by Kamran Alam, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d14+50.00%+3.77%+0.22%+3.55%+0.07%
14d14+42.86%+8.59%-0.53%+9.13%+6.93%
30d14+42.86%-1.72%-2.52%+0.81%+3.76%
60d14+50.00%-12.86%-3.50%-9.36%-2.49%
90d14+71.43%-5.27%+2.29%-7.56%-22.69%
180d14(3 pending)+90.91%-45.31%+2.26%-47.57%-56.76%
1y14(4 pending)+100.00%-57.02%+4.28%-61.30%-64.29%
2y14(4 pending)+90.00%-56.59%+21.14%-77.74%-83.62%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TSHA · 1,442,131 shares · as of Feb 4, 2026
0386,651773,3021,159,9521,546,603202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 18 buys / 16 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
CHIEF FINANCIAL OFFICER
1,655$4.52$7.5K1,442,131Feb 4, 2026Feb 6, 2026View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
CHIEF FINANCIAL OFFICER
23,849$4.61$109.9K1,443,786Jan 26, 2026Jan 27, 2026View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
CHIEF FINANCIAL OFFICER
78,968$4.75$375.1K1,467,635Jan 23, 2026Jan 27, 2026View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
231,000231,000Jan 12, 2026Jan 14, 2026View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
359,0001,546,603Jan 12, 2026Jan 14, 2026View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
CHIEF FINANCIAL OFFICER
54,491$2.85$155.3K1,187,603Aug 21, 2025Aug 22, 2025View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
CHIEF FINANCIAL OFFICER
29,843$1.69$50.4K1,242,094Mar 11, 2025Mar 12, 2025View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
431,0001,271,937Jan 2, 2025Jan 3, 2025View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
431,000431,000Jan 2, 2025Jan 3, 2025View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
CHIEF FINANCIAL OFFICER
1,288$1.51$1.9K840,937Feb 2, 2024Feb 6, 2024View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
590,413842,225Jan 2, 2024Jan 4, 2024View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
590,413590,413Jan 2, 2024Jan 4, 2024View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
187,582187,582Dec 14, 2023Dec 18, 2023View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE10b5-1
10b5-1 plan
33,000$2.33$76.9K258,042Aug 24, 2023Aug 25, 2023View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
12,46212,462May 31, 2023Apr 10, 2025View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
6,230291,042May 31, 2023Jun 2, 2023View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
37,38437,384Feb 2, 2023Feb 6, 2023View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
18,691284,812Feb 2, 2023Feb 6, 2023View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
149,900149,900Feb 2, 2023Feb 6, 2023View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
Chief Financial Officer
3,325$3.47$11.5K266,121Aug 23, 2022Aug 24, 2022View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
Chief Financial Officer
9,717$3.50$34.0K269,446Aug 22, 2022Aug 22, 2022View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
Chief Financial Officer
11,482$3.75$43.1K279,163Aug 19, 2022Aug 22, 2022View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
Chief Financial Officer
7,476$3.87$28.9K290,645Aug 18, 2022Aug 22, 2022View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
40,00040,000Apr 6, 2022Apr 8, 2022View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
80,00080,000Feb 23, 2022Feb 25, 2022View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
Chief Financial Officer
2,094$17.14$35.9K298,121Aug 20, 2021Aug 20, 2021View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
Chief Financial Officer
9,746$16.70$162.8K300,215Aug 20, 2021Aug 20, 2021View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
Chief Financial Officer
613$17.11$10.5K309,961Aug 19, 2021Aug 20, 2021View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
Chief Financial Officer
9,354$16.43$153.7K310,574Aug 19, 2021Aug 20, 2021View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
Chief Financial Officer
11,193$17.35$194.2K319,928Aug 18, 2021Aug 20, 2021View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
70,00070,000Jan 19, 2021Jan 20, 2021View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
331,121331,121Sep 23, 2020Sep 25, 2020View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
3,0003,000Feb 10, 2020Feb 10, 2020View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
25,00025,000Feb 6, 2020Feb 10, 2020View →
Other insiders · TSHA
Loading peer insiders…
About this filer
CIK 0001793412
ROLE
Chief Financial Officer
PRIMARY
TSHA
COMPANIES
2
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001793412DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback